- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02638467
Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy
Allogeneic Haematopoietic Stem Cell Transplantation From a Matched Donor in Patients With Chronic Myeloid Leukemia Failing to Gain Normal Hemopoiesis Under TKIs Therapy
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Italy/MB
-
Monza, Italy/MB, Italien, 20900
- Asst-Monza
-
-
MI
-
Milano, MI, Italien, 20132
- Ospedale San Raffaele
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Chronic Myeloid Leukaemia -CML- in chronic phase (CP)
- Failure to achieve at least a Major Cytogenetic Response (MCyR) after a minimum of 18 months of TKIs treatment
- Inability to tolerate 3 months of uninterrupted full dose TKIs therapy due to hematological toxicity
- A minimum of three treatment interruptions due to hematological toxicity Availability of a HLA-identical related donor (Matched Related Donor, MRD)
- Availability of unrelated donor (Matched Unrelated Donor, MUD) satisfying the criteria of a 10/10 antigen match at (Human Leukocyte Antigen) HLA-A, -B, -C and - DRB1, -DQB1 at high resolution typing, or 9/10 with a permissive - DP disparity according to Fleischhauer model (Crocchiolo et al, Blood 2009)
- Target graft size (bone marrow):
- bone marrow: > 3 x 106 CD34+ cells/kg BW recipient or > 3 x 108 nucleated cells/kg BW
- Karnofsky Index > 80 %
- Age ≥18 and ≤70 years
- Adequate contraception in female patients of child-bearing potential
- Written informed consent
Exclusion Criteria:
- Secondary malignancies
- A hematopoietic cell transplantation-specific comorbidity index (Sorror et al Appendix C) > 4
- Known and manifested malignant involvement of the Central Nervous System (CNS)
- Active infectious disease
- Active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis B virus (HCV) infection
- Impaired liver function (Bilirubin > upper normal limit; Transaminases > 3.0 x upper normal limit)
- Impaired renal function (Creatinine-clearance < 60 ml/min; Serum Creatinine > 1.5 x upper normal limit).
- Pleural effusion or ascites > 1.0 L
- Pregnancy or lactation
- Known hypersensitivity to Busilvex and/or fludarabine 11 Non-co-operative behaviour or non-compliance 12 Psychiatric diseases or conditions that might impair the ability to give informed consent
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Bosutinib and Bone Marrow Transplant
Subjects will receive 400mg of bosutinib from day at least -45 to day -15 to assess the sensitivity of patient Chronic Myeloid Leukemia (CML) to this TKI.
Patients will be transplanted with the aim to transplant > 3 x 106 CD34+ cells/kg Body Weight (BW) recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow.
Then, subjects will receive 400mg of bosutinib once daily from day +30 after transplant.
|
Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning.
Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
Andere Namen:
Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient. The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented. The goal is to transplant > 3 x 106 CD34+ cells/kg BW recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Efficacy as assessed by the percentage of patients with Complete Cytogenetic Response (CCyR)
Zeitfenster: 12 months
|
The percentage of patients with Complete Cytogenetic Response (CCyR) will be calculated as the complement to the percentage of failures on the total number of patients treated, where failure includes the following events: no engraftment, death within 12 months, no CCyR at 12 months.
|
12 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Gesamtüberleben
Zeitfenster: 12 Monate
|
12 Monate
|
|
Percentage of patients with engraftment
Zeitfenster: 12 months
|
12 months
|
|
percentage of patients with complete chimerism (95%)
Zeitfenster: Day +28, +56 and +100
|
Day +28, +56 and +100
|
|
Evaluation of Major Cytogenetic Response (MCyR)
Zeitfenster: 12 months
|
Major Cytogenetic Response (MCyR) is < 36% Ph+ metaphases
|
12 months
|
Evaluation of molecular responses
Zeitfenster: 12 months
|
Molecular response is defined
|
12 months
|
Relapse incidence (RI)
Zeitfenster: 12 months
|
12 months
|
|
Incidence of non-relapse mortality (NRM)
Zeitfenster: Within day +28 and +360
|
Within day +28 and +360
|
|
Incidence and severity of acute and chronic graft vs. host disease (GvHD)
Zeitfenster: 12 months
|
12 months
|
|
Quality of Life (QoL)
Zeitfenster: 12 months
|
Evaluation of QoL with EQ-5D-5L (Italian - Version 2) and FACT-Leu (Italian -Version 4)
|
12 months
|
Overall Survival (OS)
Zeitfenster: 36 months
|
2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)
|
36 months
|
Progression Free Survival (PFS)
Zeitfenster: 36 months
|
2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)
|
36 months
|
Relapse Incidence (RI)
Zeitfenster: 36 months
|
2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)
|
36 months
|
Chronic Graft-versus-host Disease (cGvHD)
Zeitfenster: 36 months
|
2 years after transplantation of the last patient included (this is intended to allow evaluations of all expected major molecular responses)
|
36 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: CARLO GAMBACORTI-PASSERINI, MD, University of Milano Bicocca
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Redaelli A, Bell C, Casagrande J, Stephens J, Botteman M, Laskin B, Pashos C. Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev Anticancer Ther. 2004 Feb;4(1):85-96. doi: 10.1586/14737140.4.1.85.
- Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature. 1983 Nov 17-23;306(5940):239-42. doi: 10.1038/306239a0.
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- alloCML
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Leukämie
-
Nanfang Hospital of Southern Medical UniversityPeking University People's Hospital; Guangzhou First People's Hospital; Sun Yat-Sen... und andere MitarbeiterUnbekanntAllogene hämatopoetische Stammzelltransplantation | Bedingungen | Mixed-Lineage-Leukemia (MLL)-Rearranged Acute LeukemiaChina
-
Shenzhen Second People's HospitalRekrutierungLeukämie | Myeloisch | Chronisch | BCR-ABL (Breakpoint Cluster Region-Abelson Murine Leukemia) | PositivChina
Klinische Studien zur Bosutinib
-
PfizerAbgeschlossen
-
PfizerAbgeschlossenGesunde TeilnehmerNiederlande
-
Kyoto UniversityPfizer; Kitasato University; Tokushima University; Tottori UniversityRekrutierungAmyotrophe LateralskleroseJapan
-
PfizerAbgeschlossenNeubildungenVereinigte Staaten
-
Children's Oncology GroupPfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...Aktiv, nicht rekrutierendChronische myeloische Leukämie in der beschleunigten Phase | Chronische myeloische Leukämie in der chronischen Phase | Blastische Phase der chronischen myeloischen Leukämie | Philadelphia-Chromosom-positive CMLVereinigte Staaten
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossen
-
Wyeth is now a wholly owned subsidiary of PfizerAbgeschlossen
-
PfizerAbgeschlossenChronisch-myeloischer LeukämieVereinigte Staaten, Kanada, Spanien, China, Australien, Singapur, Korea, Republik von, Frankreich, Hongkong, Niederlande, Truthahn, Polen, Japan, Vereinigtes Königreich, Argentinien, Kolumbien, Ungarn, Russische Föderation, ... und mehr